While therapies are limited in preventing BPD, our current finding lays the framework for the use of targeted approaches, such as reducing Keap1 expression and/or inhibiting its interaction with Nrf2, as pharmacological ways to prevent BPD pathogenesis associated with prematurity in the clinical setting. This evidence concerns the gene NFE2L2 and bronchopulmonary dysplasia.